I do not think we fully appreciate the utility of Provectus' compassionate use program outside of the great benefit it has had for patients accepted into it. Several anecdotal stories of both dramatic and beneficial treatment success have leaked out. Many more have not.
It is up to the doctors running compassionate use programs to publish the results of their treatments. As a result, it is not directly within Provectus management's purvey to publish or formally circulate such information.
We may well have to wait for these doctors (assuming they actually get around to it) to discuss in more depth the success the program has achieved in helping very needy patients, improving trial design (e.g., the pivotal MM Phase 3 trial) and further demonstrating PV-10's clinical value proposition.